Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Drugs

Showing results (341-350 of 8,370) with videos related to

Pageof 837
Sort By:
Drugs|October 15, 2020
Imlifidase: First ApprovalZaina T Al-Salama
Drugs|November 22, 2019
Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β<sub>2</sub>-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary CareDavid B Price, Victoria Carter, Jessica Martin, et al.
Drugs|March 7, 2020
Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World StudyDigsu N Koye, Olga Montvida, Sanjoy Ketan Paul
Drugs|February 1, 1977
AnthelminticsM Katz
Drugs|March 14, 2020
Correction to: Ubrogepant: First ApprovalLesley J Scott
Drugs|December 5, 2018
Correction to: Caplacizumab: First Global ApprovalSean Duggan
Drugs|December 5, 2018
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid LeukaemiaHannah A Blair
Drugs|January 20, 2019
Sarecycline: First Global ApprovalEmma D Deeks
Drugs|February 12, 2019
The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes MellitusShazia Hussain, Tahseen A Chowdhury
Drugs|February 14, 2019
Management of Hypertension in Chronic Kidney DiseaseDan Pugh, Peter J Gallacher, Neeraj Dhaun
Pageof 837

Showing results (341-350 of 8,370) with videos related to

Sort By:
Pageof 837
Drugs|October 15, 2020
Imlifidase: First ApprovalZaina T Al-Salama
Drugs|November 22, 2019
Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β<sub>2</sub>-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary CareDavid B Price, Victoria Carter, Jessica Martin, et al.
Drugs|March 7, 2020
Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World StudyDigsu N Koye, Olga Montvida, Sanjoy Ketan Paul
Drugs|February 1, 1977
AnthelminticsM Katz
Drugs|March 14, 2020
Correction to: Ubrogepant: First ApprovalLesley J Scott
Drugs|December 5, 2018
Correction to: Caplacizumab: First Global ApprovalSean Duggan
Drugs|December 5, 2018
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid LeukaemiaHannah A Blair
Drugs|January 20, 2019
Sarecycline: First Global ApprovalEmma D Deeks
Drugs|February 12, 2019
The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes MellitusShazia Hussain, Tahseen A Chowdhury
Drugs|February 14, 2019
Management of Hypertension in Chronic Kidney DiseaseDan Pugh, Peter J Gallacher, Neeraj Dhaun
Pageof 837